PT  - JOURNAL ARTICLE
AU  - Mohammad Reza Mohammad Hoseini Azar
AU  - Parham Portaghali
AU  - Amin Sedokani
AU  - Ali Jafari
TI  - Atorvastatin and standard treatment of <em>Helicobacter pylori</em>: Randomized Clinical Trial
AID  - 10.1101/2020.05.29.20117200
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.29.20117200
4099  - http://medrxiv.org/content/early/2020/07/03/2020.05.29.20117200.short
4100  - http://medrxiv.org/content/early/2020/07/03/2020.05.29.20117200.full
AB  - Background Considering the increase in drug resistance over time to Helicobacter pylori treatment relying on the anti-inflammatory and antibacterial effects of atorvastatin to increase the success rate of H. pylori eradication, we examined the effect of adding atorvastatin to standard treatment of H. pylori eradication.Materials and Methods A total of 186 symptomatic patients who had been diagnosed with Helicobacter pylori infection and tested for H. pylori eradication were examined by a pathological response or positive urea breath test. Patients who received atorvastatin in addition to standard treatment were also identified based on a table of random numbers. Standard treatment included a 240mg bismuth subcitrate tablet, a 40mg pantoprazole tablet, a 500mg metronidazole tablet, and 2 capsules of 500mg amoxicillin, all taken BID for 14 days. After 4 weeks of treatment, all patients underwent stool testing for H. pylori fecal antigen. If the test was positive, the request was considered a failure of treatment, and if the test was negative, it was considered a successful eradication of H. pylori. The clinical trial registration code for this study is IRCT20190823044589N1.Results The eradication rate of H. pylori was 80% in the control group and 80.9% in the intervention group, which did not show a statistically significant difference between the two groups (P-value=0.971).Conclusion Adding atorvastatin to 4-drug regimen of PPI, bismuth subcitrate, amoxicillin, and metronidazole as the first line of treatment for H. pylori eradication is ineffective.Significance of this Study (Summary box)What is already known about this subject?Infection of H. pylori is common worldwide and the antibiotic resistance is increasingAtorvastatin, has anti-inflammatory and antibacterial effects. But also, have D grade interaction with clarithromycin in H. pylori eradication regimen and increases the toxic and lethal risk of atorvastatin toxicity.What are the new findings?Eradication rate of H. pylori using the standard treatment of a 240mg bismuth subcitrate tablet, a 40mg pantoprazole tablet, a 500mg metronidazole tablet, and 2 capsules of 500mg amoxicillin, BID for 14 days, is at least 80%.Adding atorvastatin to 4-drug regimen of PPI, bismuth subcitrate, amoxicillin, and metronidazole as the first line of treatment for H. pylori eradication is ineffective.How might it impact on clinical practice in the foreseeable future?There should be more analysis on cost-benefice of adding atorvastatin to standard regimen of treatment for H. pylori eradication, but adding the atorvastatin to metronidazole-based H. pylori treatment is ineffective and for clarithromycin-based treatment is dangerous.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialIRCT20190823044589N1Funding StatementThere is no funding for this study as there is no kind of conflict of interestAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:After the approval of the university's ethics committee (IR.UMSU.REC), the plan was implemented without imposing additional costs on patients and informed consent obtained from each patient. The study group will be published and the individual results will be presented if necessary, without mentioning the name and personal details. The ethical approvement is under code of IR.UMSU.REC.1398.186 and the clinical trial registration code is IRCT20190823044589N1.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data of this study is available to the professional reviewers.